PC-Merz, 100 mg 30 pcs.

Name: PC-Merz, 100 mg 30 pcs.
SKU: 26421
Availability: InStock

€5.83

EAN: 4008491313568 SKU: 26421 Categories: Medicine, Neurology and Psychiatry, Parkinson's Disease

Description

PK-Mertz is a blocker of glutamate N-methyl-D-aspartate receptors (NMDA-receptors). Antiparkinsonian drug. Amantadine has an indirect agonist effect on striatal dopamine receptors. Increases extracellular concentration of dopamine by both intensification of its production and blockade of dopamine reuptake by presynaptic neurons. In therapeutic concentrations amantadine slows down production of acetylcholine and thus has anticholinergic effect.

Pharmacokinetics

Intake

After a single dose, Cmax is reached within approximately 2-8 hours. After administration of amantadine sulfate at a dose of 100 mg, Cmax is 0.15 µg/mL.

The mean plasma concentration of amantadine sulfate after an IV infusion of 200 mg for 3 hours is 0.54 µL. At a dose of 200 mg/day the mean plasma concentration by the end of day 6 of treatment is 0.76 µL.

Distribution

The binding to plasma proteins is 67%. It penetrates through the BBB.

T1/2 is 10-30 h, on average 10 h. It is excreted practically unchanged by the kidneys (90% of the single dose); a small amount is excreted in the feces. Dialysis is ineffective (about 5% in one session).

The total clearance when administered by IV is 3.6 l/h.

Indications

Neuralgia, Psychiatric disorders, Parkinson’s disease

Parkinson’s disease (muscle rigidity, tremor, hypo- or akinesia);

extrapyramidal disorders caused by taking neuroleptics or other drugs;
neuralgia in herpes zoster.

Active ingredient

Amantadine

Composition

Amantadine sulfate 100 mg

Supplementary substances:

Microcrystalline cellulose,

potato starch,

p> gelatin,

lactose monohydrate,

povidone,

talc,

magnesium stearate,

colloidal silica,

croscarmellose sodium,

p> titanium dioxide,

butyl methacrylate copolymer,

dye orange yellow

How to take, the dosage
How to take, the dosage
Overly, after meals with a small amount of liquid, preferably in the first half of the day.
The first 3 days is 1 tablet a day, then the dose is increased to 2 tablets a day, with a further increase of 1 tablet a week possible.
The usual effective dose is 1 to 3 tablets twice a day.
The maximum daily dose is 600 mg.
In case of combined treatment, the dose must be determined individually.
The last dose is recommended to be taken in the afternoon no later than 4 pm.
The use in elderly patients, particularly in patients with states of agitation and confusion, predelirium and delirium. A lower dosage is required.

Interaction
Interaction
Concomitant administration of diuretics that are a combination of triamterene/hydrochlorthiside may lead to changes in plasma concentrations of amantadine.
In combined therapy with other anti-Parkinsonian drugs it may be necessary to change the doses of the other drugs or the combination as a whole accordingly, otherwise side effects may increase.

Special Instructions
Special Instructions
PK-Mertz treatment should not be stopped abruptly as this may cause a worsening of symptoms.
Patients with cardiovascular disease should be kept under constant medical supervision when prescribing PC-Mertz.
The use of alcohol is contraindicated during treatment.
Impact on the ability to drive vehicles and operate machinery. Use with caution during work for drivers of vehicles and people whose profession requires high concentration.

Contraindications
Contraindications
severe congestive heart failure (functional class IV by NYHA classification);
cardiomyopathy;
myocarditis;
AV-blockade of degree II and III;
bradycardia (HR less than 55 beats./min);
long QT interval greater than 420 ms;
ventricular arrhythmia (including ventricular flutter;
hypokalemia;
hypomagnesemia;
simultaneous use with QT interval prolonging drugs;
severe renal insufficiency (CK < 10 ml/min);
childhood;

phenylketonuria
pregnancy
breast-feeding period
high sensitivity to any of the drug components.
With caution, the drug should be prescribed in case of hyperplasia of the prostate, closed-angle glaucoma, renal insufficiency of different degrees of severity (there is a risk of cumulation of the drug), agitation, delirium, CNS depression, exogenous psychosis (including history).history), when co-administered with memantine, triamterene/hydrochlorothiazide.

Side effects
Side effects
Mental disorders accompanied by visual hallucinations.
Rarely – motor and mental agitation.
Urinary retention in patients with adenoma of the prostate.
Heart failure.
Arrhythmia, tachycardia, nausea, dry mouth, dizziness, sleep disturbance.
Very rare – appearance of bluish coloring of the skin of the upper and lower extremities, decreased visual acuity.

Overdose
Overdose
Symptoms: nausea, vomiting, tremor, ataxia, decreased visual acuity, lethargic state, dysarthria, epileptic seizures, arrhythmia.
Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Similarities
Similarities
Midanthan

Additional information
Weight 0.024 kg
Shelf life
5 years.
Conditions of storage
Store at a temperature not exceeding 25 ° C.
Manufacturer
Kloke Pharma-Service GmbH, Germany
Medication form
pills
Brand
Kloke Pharma-Service GmbH